Quadroiliac Plane BlockNCT07815145
Quadroiliac Plane Block Versus Transmuscular Quadratus Lumborum Block for Postoperative Analgesia After Total Hip Arthroplasty
A study testing Quadroiliac Plane Block and Transmuscular quadratus lumborum block in people with Quadroiliac Plane Block and Transmuscular Quadratus Lumborum Block, run by Tanta University at 1 site in Egypt.
Trial summary
This study aims to evaluate and compare the postoperative analgesic efficacy, opioid consumption, motor function preservation, and quality of recovery of ultrasound-guided Quadroiliac Plane Block (QIPB) versus transmuscular quadratus lumborum block (QLB) in patients undergoing THA under spinal anesthesia. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Quadroiliac Plane Block, Transmuscular Quadratus Lumborum Block, Postoperative Analgesia
- What is being tested?
- Quadroiliac Plane Block and Transmuscular quadratus lumborum block
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteEgypt
- Study dates
- 12 Sep 2026to 1 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-75 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) classification I-III.
- Scheduled for elective primary unilateral total hip arthroplasty under spinal anesthesia.
Who cannot join
- Allergy to local anesthetics.
- Infection at the injection site.
- Coagulopathy or bleeding disorders.
- Neuromuscular disorders.
- Chronic opioid use or dependence.
- Body mass index (BMI) > 40 kg/m².
- Severe cardiac, hepatic, renal, or respiratory dysfunction.
- Contraindication to regional anesthesia.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Tanta University
Tanta, El-Gharbia, 31527
Mohammed S Elsharkawy, MD, 00201148207870, mselsharkawy@med.tanta.edu.eg
About this study
Official title: Quadroiliac Plane Block Versus Transmuscular Quadratus Lumborum Block for Postoperative Analgesia After Total Hip Arthroplasty: A Randomized Clinical Trial
This study aims to evaluate and compare the postoperative analgesic efficacy, opioid consumption, motor function preservation, and quality of recovery of ultrasound-guided Quadroiliac Plane Block (QIPB) versus transmuscular quadratus lumborum block (QLB) in patients undergoing THA under spinal anesthesia.
Read the detailed description
Total hip arthroplasty (THA) is a common orthopedic procedure for end-stage hip diseases such as osteoarthritis and avascular necrosis. It is highly effective in relieving pain and restoring function.
The quadratus lumborum block (QLB) is one such fascial plane technique. It provides analgesia through spread of local anesthetics within the thoracolumbar fascia. This allows potential involvement of lumbar plexus branches.
The Quadroiliac Plane Block (QIPB) is a newer regional technique for hip and pelvic surgery. It targets fascial planes near the iliac region to block sensory innervation of the hip. Early studies suggest it may provide effective postoperative analgesia.
- Conditions
- Quadroiliac Plane Block, Transmuscular Quadratus Lumborum Block, Postoperative Analgesia, Total Hip Arthroplasty
- Being tested
- Quadroiliac Plane Block, Transmuscular quadratus lumborum block
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quadroiliac Plane BlockDrug
Patients will receive an ultrasound-guided Quadroiliac Plane Block (QIPB) using 20 mL of bupivacaine 0.25%.
Transmuscular quadratus lumborum blockDrug
Patients will receive ultrasound-guided quadratus lumborum block (QLB) (transmuscular approach) using 20 mL of 0.25% bupivacaine.
| Study group | Role | What they receive |
|---|---|---|
| Group QIP | Experimental | Patients will receive an ultrasound-guided Quadroiliac Plane Block (QIPB) using 20 mL of bupivacaine 0.25%. Receives: Drug: Quadroiliac Plane Block |
| Group QLB | Experimental | Patients will receive ultrasound-guided quadratus lumborum block (QLB) (transmuscular approach) using 20 mL of 0.25% bupivacaine. Receives: Drug: Transmuscular quadratus lumborum block |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total morphine consumption
Rescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) > 3 to be repeated after 30 min if pain persists until the NRS < 4.
Measured: 24 hours postoperatively
Secondary outcomes (5)
Degree of pain
Each patient will be instructed about postoperative pain assessment with the numeric rating scale (NRS) score. NRS (0 represents "no pain" while 10 represents "the worst pain imaginable"). NRS will be assessed at post-anesthesia care unit (PACU), 2, 4, 6, 12, and 24 h postoperatively.
Measured: 24 hours postoperatively
Time to the 1st rescue analgesia
Time to the first request for rescue analgesia will be recorded from the end of block to first dose of morphine administrated.
Measured: 24 hours postoperatively
Time for ambulation
Time to ambulation: the time interval (in hours) from the end of surgery to the first successful mobilization of the patient, defined as the ability to stand and walk at least 3-5 steps with or without assistance.
Measured: 24 hours postoperatively
Length of hospital stay
Length of hospital stay will be recorded from admission till the discharge from hospital.
Measured: Till the discharge from hospital (Up to 2 weeks)
Incidence of adverse events
Incidence of adverse events such as bradycardia, hypotension, nausea, vomiting, respiratory depression, or any other complication will be recorded.
Measured: 24 hours postoperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2026
- Study start12 Sep 2026
- Primary completion1 Feb 2027 (estimated)
- Study completion1 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Quadroiliac Plane BlockStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tanta University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohammed Said ElSharkawy, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07815145
- Sponsor's protocol ID
- 36265PR152/7/26
- Status last verified
- Sep 2026
- First submitted
- 6 Sep 2026
- Last updated
- 15 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 15 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Quadroiliac Plane Block Versus Transmuscular Quadratus Lumborum Block for Postoperative Analgesia After Total Hip Arthroplasty: A Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT07815145
- Acronym / sponsor ID
- 36265PR152/7/26
- Conditions
- Quadroiliac Plane Block, Transmuscular Quadratus Lumborum Block, Postoperative Analgesia, Total Hip Arthroplasty
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Tanta UniversityUniversity, hospital or other
- Study start
- 12 Sep 2026 (actual)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 1 Feb 2027 (estimated)
- First posted
- 11 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate and compare the postoperative analgesic efficacy, opioid consumption, motor function preservation, and quality of recovery of ultrasound-guided Quadroiliac Plane Block (QIPB) versus transmuscular quadratus lumborum block (QLB) in patients undergoing THA under spinal anesthesia.
Detailed description
Total hip arthroplasty (THA) is a common orthopedic procedure for end-stage hip diseases such as osteoarthritis and avascular necrosis. It is highly effective in relieving pain and restoring function.
The quadratus lumborum block (QLB) is one such fascial plane technique. It provides analgesia through spread of local anesthetics within the thoracolumbar fascia. This allows potential involvement of lumbar plexus branches.
The Quadroiliac Plane Block (QIPB) is a newer regional technique for hip and pelvic surgery. It targets fascial planes near the iliac region to block sensory innervation of the hip. Early studies suggest it may provide effective postoperative analgesia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group QIP | Experimental | Drug: Quadroiliac Plane BlockPatients will receive an ultrasound-guided Quadroiliac Plane Block (QIPB) using 20 mL of bupivacaine 0.25%. |
| Group QLB | Experimental | Drug: Transmuscular quadratus lumborum blockPatients will receive ultrasound-guided quadratus lumborum block (QLB) (transmuscular approach) using 20 mL of 0.25% bupivacaine. |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age 18-75 years.
- Both sexes.
- American Society of Anesthesiologists (ASA) classification I-III.
- Scheduled for elective primary unilateral total hip arthroplasty under spinal anesthesia.
Key exclusion criteria (8 listed)
- Allergy to local anesthetics.
- Infection at the injection site.
- Coagulopathy or bleeding disorders.
- Neuromuscular disorders.
- Chronic opioid use or dependence.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quadroiliac Plane BlockPatients will receive an ultrasound-guided Quadroiliac Plane Block (QIPB) using 20 mL of bupivacaine 0.25%. | Drug | Group QIP |
| Transmuscular quadratus lumborum blockPatients will receive ultrasound-guided quadratus lumborum block (QLB) (transmuscular approach) using 20 mL of 0.25% bupivacaine. | Drug | Group QLB |
Primary outcome
Total morphine consumption
Time frame: 24 hours postoperatively
Rescue analgesia of morphine will be given as 3 mg bolus if the numeric rating scale (NRS) > 3 to be repeated after 30 min if pain persists until the NRS < 4.
5 secondary outcomes
Degree of pain
Time frame: 24 hours postoperatively
Time to the 1st rescue analgesia
Time frame: 24 hours postoperatively
Time for ambulation
Time frame: 24 hours postoperatively
Length of hospital stay
Time frame: Till the discharge from hospital (Up to 2 weeks)
Incidence of adverse events
Time frame: 24 hours postoperatively
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Sep 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Quadroiliac Plane Block and Transmuscular quadratus lumborum block in people with Quadroiliac Plane Block and Transmuscular Quadratus Lumborum Block, run by Tanta University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohammed S Elsharkawy, MD (00201148207870, mselsharkawy@med.tanta.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total morphine consumption (time frame: 24 hours postoperatively). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.